糖尿病肾病治疗的研究进展综述
Progress in the Treatment of Diabetic Nephropathy
DOI: 10.12677/HJS.2019.83012, PDF,   
作者: 葛景利, 代青湘：青海大学附属医院老年科，青海 西宁
关键词: 糖尿病肾病；治疗；研究进展；Diabetic Nephropathy； Treatment； Research Progress
摘要: 糖尿病已成为一个全球性的严重公共卫生问题，随着生活方式的改变和老龄化等多种因素驱动下，我国糖尿病患病率呈逐年递增趋势，2017年中国糖尿病患病率为10.9%估算糖尿病患者数量1.14亿，位居世界第一，糖尿病肾病是糖尿病最常见的并发症之一，是导致终末期肾脏病(ESRD)的主要病因，一旦患者进展至ESRD，需要接受肾脏替代治疗，严重影响患者的生活质量，给家庭带来严重的经济负担，因此糖尿病肾病治疗的研究已经成为一个非常严峻问题，但是目前对糖尿病肾病缺乏有效的治疗方法，本文总结了目前我国部分糖尿病肾病治疗的研究进展，为临床治疗及后续研究提供参考。
Abstract: Diabetes mellitus has become a serious global public health problem. Driven by lifestyle changes and aging, the prevalence of diabetes in China is increasing year by year. In 2017, the prevalence of diabetes mellitus in China is 10.9%. The estimated number of diabetic patients is 114 million, ranking first in the world. Diabetic nephropathy is one of the most common complications of dia-betes mellitus, and it is the end-stage kidney. The main etiology of diabetic nephropathy (ESRD) is that once patients progress to ESRD, they need renal replacement therapy, which seriously affects the quality of life of patients and brings serious financial burden to their families. Therefore, the research of diabetic nephropathy treatment has become a very serious problem, but there is no effective treatment for diabetic nephropathy at present. This paper summarizes some diabetic nephropathy in China. The research progress of disease treatment can provide reference for clinical treatment and follow-up research.
文章引用：葛景利, 代青湘. 糖尿病肾病治疗的研究进展综述[J]. 外科, 2019, 8(3): 78-83. https://doi.org/10.12677/HJS.2019.83012

参考文献

[1] 蒲蕾, 王莉. 噻唑烷二酮类药物对肾脏的保护作用[J]. 实用医院临床杂志, 2009, 6(1): 90-93.
[2] 王少清, 周萍, 毛楠, 陈利佳, 臧丽. 吡格列酮治疗早期糖尿病肾病的临床疗效观察及其对尿微量白蛋白的影响[J]. 四川医学, 2017, 38(7): 757-760.
[3] 董莉, 赵积海. 利拉鲁肽对微量白蛋白尿期糖尿病肾病患者肾功能的影响[J]. 临床荟萃, 2018, 33(5): 420-423.
[4] Hocher, B., Reichetzeder, C. and Alter, M.L. (2012) Renal and Cardiac Effects of DPP4 Inhibitors—From Preclinical Development to Clinical Research. Kidney and Blood Pressure Research, 36, 65-84. [Google Scholar] [CrossRef] [PubMed]
[5] Duvnjak, L., Perkovic, M.N. and Blaslov, K. (2017) Dipeptidylpeptidase-4 Activity Is Associated with Urine Albumin Excretion in Type 1 Diabetes. Journal of Diabetic Complications, 31, 218-222. [Google Scholar] [CrossRef] [PubMed]
[6] 胡军, 杨少娟. 西格列汀对早期糖尿病肾病患者的影响[J]. 临床内科杂志, 2014, 31(7): 474-476.
[7] Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. (2016) Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. The New England Journal of Medicine, 375, 323-334. [Google Scholar] [CrossRef] 
[8] Persson, F., Rossing, P., Schjoedt, K.J., et al. (2008) Time Course of the Antiproteinuric and Antihypertensive Effects of Direct Renin Inhibition in Type 2 Diabetes. Kidney International, 73, 1419-1425. [Google Scholar] [CrossRef] [PubMed]
[9] Parving, H.H., Persson, F., Lewis, J.B., et al. (2008) Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. The New England Journal of Medicine, 358, 2433-2446. [Google Scholar] [CrossRef] 
[10] Parving, H.H., Brenner, B.M., Mcmurray, J.J., et al. (2012) Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. The New England Journal of Medicine, 367, 2204-2213. [Google Scholar] [CrossRef] 
[11] 杨琳琳. 醛固酮受体拮抗剂治疗糖尿病肾病的临床安全性[J]. 中国医药指南, 2016, 14(32): 89-90.
[12] 罗璇. 厄贝沙坦联合螺内酯治疗糖尿病肾病的临床价值研究[J]. 当代医学, 2018, 24(22): 127-128.
[13] 凌雅韵. 第三代盐皮质激素受体拮抗剂finerenone的研究进展[D]: [硕士学位论文]. 重庆: 重庆医科大学, 2017.
[14] Bakris, G.L., Agarwal, R., Chan, J.C., et al. (2015) Effect of Finere-none on Albuminuria in Patients with Diabetic Nephropathy: A Randomized Clinical Trial. JAMA, 314, 884-894. [Google Scholar] [CrossRef] [PubMed]
[15] 王鲁奎. 糖尿病肾病发病机制探讨及最新治疗进展[J]. 基层医学论坛, 2018, 22(7): 989-990.
[16] 刘文, 章尹岗. 依帕司他对糖尿病肾病患者氧化应激及肾功能的影响[J]. 西北药学杂志, 2018, 33(4): 539-542.
[17] 赵桂东. 普罗布考在早期糖尿病肾病治疗中的应用[J]. 山东医药, 2015, 55(34): 64-65.
[18] 杨海波, 方晓琳, 杨玉, 孙广平, 张一诺. 不同剂量骨化三醇联合盐酸吡格列酮对糖尿病肾病患者的疗效[J]. 广西医学, 2018, 40(13): 1419-1423.
[19] 白煜. 骨化三醇胶丸联合替米沙坦片治疗早期糖尿病肾病的疗效[J]. 中国实用医药, 2019, 14(3): 91-92.
[20] Forbes, J.M. and Cooper, M.E. (2013) Mechanisms of Dia-betic Complications. Physiological Reviews, 93, 137-188. [Google Scholar] [CrossRef] [PubMed]
[21] Van Buren, P.N. and Toto, R. (2013) Current Update in the Management of Diabetic Nephropathy. Current Diabetes Reviews, 9, 62-77. [Google Scholar] [CrossRef] [PubMed]
[22] Sharma, K., Ix, J.H., Mathew, A.V., et al. (2011) Pirfenidone for Diabetic Nephropathy. Journal of the American Society of Nephrology, 22, 1144-1151. [Google Scholar] [CrossRef] 
[23] Kohan, D.E., Pritchett, Y., Molitch, M., et al. (2011) Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic Nephropathy. Journal of the American Society of Nephrology, 22, 763-772. [Google Scholar] [CrossRef] 
[24] 王建中. 内皮素A受体拮抗剂阿曲生坦降低2型糖尿病肾病患者的残余白蛋白尿[J]. 中华肾病研究电子杂志, 2014, 3(2): 113.
[25] Schievink, B., de Zeeuw, D., Smink, P.A., et al. (2016) Prediction of the Effect of Atrasentan on Renal and Heart Failure Outcomes Based on Short-Term Changes in Multiple Risk Markers. European Journal of Preventive Cardiology, 23, 758-768. [Google Scholar] [CrossRef] [PubMed]
[26] 陈智伟. 胰激肽原酶治疗糖尿病肾病的效果及对肾功能的影响[J]. 白求恩医学杂志, 2016, 14(1): 81-82.
[27] Gambaro, G., Kinalska, I., Oksa, A., et al. (2002) Oral Sulodexide Reduces Albuminuria in Microalbuminuric and Macroalbuminuric Type 1 and Type 2 Diabetic Patients: The Di.N.A.S. Randomized Trial. Journal of the American Society of Nephrology, 13, 1615-1625. [Google Scholar] [CrossRef] 
[28] 陈玲, 吴小燕, 高苹. 舒洛地特对显性糖尿病肾病治疗作用的回顾性分析[J]. 武汉大学学报(医学版), 2018, 39(5): 805-808.
[29] 史晓贤, 李高文. 基于疾病基因表达谱的糖尿病肾病治疗药物预测[J]. 中国医药导报, 2018, 15(22): 18-21, 26, 181.